Episode 32 - Conversations in IFN-y Driven Diseases: Decoding the Gamma Signal - Part 3: Primary HLH

This third podcast episode in the series explores advanced understanding of primary hemophagocytic lymphohistiocytosis (HLH), focusing on its genetic basis, diagnostic innovations, and treatment strategies. The discussion highlights the pathophysiology of HLH as an interferon gamma (IFN-γ) driven disease, emphasizing the role of novel diagnostic tools such as flow cytometry and genetic panels. The panel also examines emerging therapies, including JAK inhibitors and IFN-γ monoclonal antibody (emapalumab), in improving outcomes for both primary and secondary HLH. Practical insights into balancing immunosuppression with efficacy offer guidance for optimizing patient care.Launch Date: December 2, 2024Release Date: December 2, 2024Expiration Date: November 30, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children’s Hospital Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1